These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 39213467)
1. Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML. Yokote H; Mori K; Nakamichi K; Matsuda T; Miura Y Neurology; 2024 Oct; 103(7):e209874. PubMed ID: 39213467 [No Abstract] [Full Text] [Related]
2. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis. Ercan MB; Kocer B; Altiparmak T; Arslan I Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206 [No Abstract] [Full Text] [Related]
3. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab. Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501 [No Abstract] [Full Text] [Related]
4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases. N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995 [TBL] [Abstract][Full Text] [Related]
7. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy. Budhram A; Pelikan JB; Kremenchutzky M; Sharma M J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156 [No Abstract] [Full Text] [Related]
8. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML. Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257 [TBL] [Abstract][Full Text] [Related]
9. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES. Yap SM; McGuigan C Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039 [No Abstract] [Full Text] [Related]
10. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis]. Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046 [TBL] [Abstract][Full Text] [Related]
11. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808 [TBL] [Abstract][Full Text] [Related]
15. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275 [TBL] [Abstract][Full Text] [Related]
16. Immune reconstitution inflammatory syndrome and natalizumab-Is it possible before removing the drug? Mulero P; Neri MJ; Rodriguez M; Arenillas JF; Téllez N Mult Scler Relat Disord; 2014 Sep; 3(5):659-61. PubMed ID: 26265277 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016 [No Abstract] [Full Text] [Related]